Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine.

Trial Details

NCT ID

NCT06752811

Phase

PHASE3

Sponsor

Shanghai Yizhong Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

paclitaxel polymeric micelles for injection
Gemcitabine Hydrochloride for Injection
Paclitaxel for Injection (albumin bound )

Locations (sample)

Nanjing, Jiangsu, China|32.06167,118.77778
Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

1\) Men or women aged 18 to 75 years old (including the critical value).
2）Metastatic pancreatic cancer confirmed by histology or cytology.
3）Patients who have not previously received any systemic therapy (including chemotherapy, targeted, and immunotherapy), radiotherapy, surgery, or i…
4）Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →